Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
基本信息
- 批准号:6795297
- 负责人:
- 金额:$ 25.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-02-01 至 2008-01-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS vaccines B lymphocyte HIV envelope protein gp120 HIV infections Salmonella Salmonella infections Salmonella vaccines active immunization cell nucleus cytoplasm gene expression helper T lymphocyte human immunodeficiency virus 1 humoral immunity laboratory mouse mucosal immunity mutant neutralizing antibody vaccine development vector vaccine viral vaccines virus DNA virus antigen
项目摘要
DESCRIPTION (provided by applicant): The goal of the research in this proposal is to identify a Salmonella HIV-1 DNA vaccine vector configuration that induces durable, high-titer neutralizing antibody responses to HIV-1 in the mucosal and systemic immune compartments. The capacity of Salmonella vectors to deliver DNA vaccines and induce immune responses in the mucosal and systemic compartments supports the idea to deploy this vector to deliver DNA vaccines that express conformationally constrained HIV-1 Env immunogens. Moreover, strong humoral responses to gp120 developed in mice primed with a Salmonella gp120 DNA vaccine vector following two parenteral booster vaccinations with gp120 protein; in contrast, no such responses occurred in mice primed with the control Salmonella construct and boosted twice with gp120 protein (Section 3.3). The significance of having identified an effective vaccination protocol for the induction of high-titer antibody responses to a model HIV-1 antigen following a mucosal prime will not be overlooked. However, the Principal Investigator (PI) proposes that the complete utilization of this inexpensive oral vaccine vector necessitates that such responses arise without a heterologous vaccine modality boosts. In this regard, the responses induced by a first-generation Salmonella Env/gp120 DNA vaccine vectors to HIV-1 were predominantly cell-mediated ((1); App. 1). Nonetheless, the afore mentioned humoral priming attribute suggests the occurrence of low-dose immunogen expression, which induced memory T helper and B cell responses (12-16). By extension, the central hypothesis of this proposal is that the magnitude of the antibody responses to HIV-1 following vaccination with a Salmonella HIV-1 DNA vaccine vector is directly linked to the efficiency DNA vaccine delivery and immunogen expression in host cells. To test this hypothesis the potency and duration of mucosal and systemic antibody responses will be measured in mice vaccinated with Salmonella vectors that carry modifications designed to optimize DNA vaccine delivery and immunogen expression. It is projected that this approach will provide fundamental information germane to the development of an inexpensive oral HIV-1 vaccine.
描述(由申请方提供):本提案中研究的目标是确定沙门氏菌HIV-1 DNA疫苗载体配置,该配置可在粘膜和全身免疫区室中诱导持久、高滴度的HIV-1中和抗体应答。 沙门氏菌载体递送DNA疫苗并在粘膜和全身隔室中诱导免疫应答的能力支持了将该载体用于递送表达构象受限的HIV-1 Env免疫原的DNA疫苗的想法。 此外,在用沙门氏菌gp 120 DNA疫苗载体致敏的小鼠中,在用gp 120蛋白进行两次胃肠外加强接种后,对gp 120产生了强烈的体液应答;相反,在用对照沙门氏菌构建体致敏并用gp 120蛋白进行两次加强接种的小鼠中,未发生此类应答(第3.3节)。 确定一种有效的疫苗接种方案,用于在粘膜初免后诱导对模型HIV-1抗原的高滴度抗体应答,这一点的重要性不容忽视。 然而,主要研究者(PI)提出,完全利用这种廉价的口服疫苗载体需要在没有异源疫苗形式加强的情况下产生这种应答。 在这方面,由第一代沙门氏菌Env/gp 120 DNA疫苗载体诱导的对HIV-1的应答主要是细胞介导的((1);附录1)。 尽管如此,上述体液致敏属性提示发生低剂量免疫原表达,其诱导记忆性T辅助细胞和B细胞应答(12-16)。 通过扩展,该提议的中心假设是,用沙门氏菌HIV-1 DNA疫苗载体接种后对HIV-1的抗体应答的幅度与DNA疫苗递送效率和宿主细胞中的免疫原表达直接相关。 为了检验这一假设,将在用沙门氏菌载体接种的小鼠中测量粘膜和全身抗体应答的效力和持续时间,所述沙门氏菌载体携带设计用于优化DNA疫苗递送和免疫原表达的修饰。 预计这种方法将为开发廉价的口服HIV-1疫苗提供基本信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Michael Hone其他文献
David Michael Hone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Michael Hone', 18)}}的其他基金
Development of a Bacteriophage Vaccine Vector System
噬菌体疫苗载体系统的开发
- 批准号:
7659340 - 财政年份:2009
- 资助金额:
$ 25.37万 - 项目类别:
Improved Bladder Cancer Therapy With Recombinant BCG
重组卡介苗改善膀胱癌治疗
- 批准号:
7326545 - 财政年份:2007
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
6867374 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
7277571 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
6699004 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
7111595 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
7768199 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
6656103 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
沙门氏菌-HIV-1 DNA 疫苗载体的优化
- 批准号:
7186726 - 财政年份:2003
- 资助金额:
$ 25.37万 - 项目类别:
相似海外基金
Modulation of T-/B-lymphocyte immigration affects subsequent allograft damage (B06)
T/B 淋巴细胞迁移的调节会影响随后的同种异体移植物损伤 (B06)
- 批准号:
517500221 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
CRC/Transregios
development of therapeutic strategy for immune related adverse events by immune checkpoint inhivitor by focusing on B lymphocyte
以B淋巴细胞为重点,制定免疫检查点抑制剂免疫相关不良事件的治疗策略
- 批准号:
22K08541 - 财政年份:2022
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Role and Regulation of Monocarboxylate Transporters 1 and 4 in Epstein-Barr Virus-mediated B Lymphocyte Tumorigenesis
单羧酸转运蛋白1和4在EB病毒介导的B淋巴细胞肿瘤发生中的作用和调节
- 批准号:
10154328 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Dissecting Hem-1 functions in B lymphocyte Development and Primary Immunodeficiency Disease
剖析 Hem-1 在 B 淋巴细胞发育和原发性免疫缺陷病中的功能
- 批准号:
10385848 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
The role of Semaphorin 4C-PlexinB2 interaction in B-lymphocyte differentiation
Semaphorin 4C-PlexinB2 相互作用在 B 淋巴细胞分化中的作用
- 批准号:
RGPIN-2017-06735 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Discovery Grants Program - Individual
The Role and Regulation of Monocarboxylate Transporters 1 and 4 in Epstein-Barr Virus-mediated B Lymphocyte Tumorigenesis
单羧酸转运蛋白1和4在EB病毒介导的B淋巴细胞肿瘤发生中的作用和调节
- 批准号:
10364632 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
儿童镰状细胞病 B 淋巴细胞缺乏的特征
- 批准号:
10641800 - 财政年份:2020
- 资助金额:
$ 25.37万 - 项目类别:
Functional Consequences of Ubiquitin Depletion During B Lymphocyte Differentiation
B 淋巴细胞分化过程中泛素耗竭的功能后果
- 批准号:
10055003 - 财政年份:2020
- 资助金额:
$ 25.37万 - 项目类别:
Functional Consequences of Ubiquitin Depletion During B Lymphocyte Differentiation
B 淋巴细胞分化过程中泛素耗竭的功能后果
- 批准号:
10684125 - 财政年份:2020
- 资助金额:
$ 25.37万 - 项目类别:
How does aberrant B lymphocyte produce a origin of multiple myeloma cells?
异常B淋巴细胞如何产生多发性骨髓瘤细胞的起源?
- 批准号:
20K08738 - 财政年份:2020
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)